Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,148.42
(
0.00%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 134686

Thursday, 04/19/2012 10:37:27 PM

Thursday, April 19, 2012 10:37:27 PM

Post# of 257580
Presidio provides update on its NS5A inhibitor, PPI-668:

http://finance.yahoo.com/news/presidio-pharmaceuticals-announces-phase-1a-040000825.html

PPI-668 is the successor to PPI-461, a drug that Presidio acquired from XTLB at a firesale price about four years ago (#msg-27791536).

p.s. If XTLB had waited until now to sell a preclinical NS5A inhibitor, they probably could have walked away with real money :- )

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today